Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study
- 30 January 2021
- journal article
- research article
- Published by Anticancer Research USA Inc. in Anticancer Research
- Vol. 41 (2), 927-936
- https://doi.org/10.21873/anticanres.14846
Abstract
Background/Aim: Limited published real-world data describe adverse events (AEs) among patients treated for mantle-cell lymphoma (MCL). The aim of this retrospective study was to describe treatment patterns, AEs, and associated healthcare costs. Patients and Methods: Patients had two or more claims coded for MCL diagnosis, the first claim date (07/01/2012–05/31/2017) was the index date. Patients with pre-index MCL diagnosis or systemic treatment, or hematopoietic stem cell transplantation were excluded. Cohorts by regimen were followed for up to three lines of therapy. Results: Patients (n=395; median age 72 years; 31% female) were observed over a total of 576 lines of therapy, the most common being bendamustine plus rituximab; rituximab monotherapy; R-CHOP; and ibrutinib. The most frequent AEs were hypertension (40.5%), anemia (37.7%), and infection (36.1%). However, hepatotoxicity ($19,645), stroke ($18,893), and renal failure ($9,037) were associated with the highest medical costs per patient per month. Conclusion: Among patients receiving common systemic treatments for MCL, AEs occurred frequently; some imposed substantial inpatient care costs.Keywords
This publication has 13 references indexed in Scilit:
- Assessment of costs associated with adverse events in patients with cancerPLOS ONE, 2018
- Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and TherapiesAsco Educational Book, 2017
- 2016 US lymphoid malignancy statistics by World Health Organization subtypesCA: A Cancer Journal for Clinicians, 2016
- Mantle Cell LymphomaJournal of Clinical Oncology, 2016
- Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World DataMedical Care, 2016
- Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion ProductClinical Lymphoma Myeloma and Leukemia, 2015
- Association of Patient-Centered Outcomes With Patient-Reported and ICD-9-Based Morbidity MeasuresAnnals of Family Medicine, 2012
- Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 CountriesAmerican Journal of Epidemiology, 2011
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaBlood, 2008